Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinobiomed to Start Phase II Malaria Vaccine Trial

publication date: May 16, 2008

Sinobiomed Inc. will begin a Phase II clinical trial of its malaria vaccine candidate, PfCP2.9, in Thailand in Q3 2008. Thailand is currently experiencing a malaria epidemic. In its Phase I trial, which was completed in 2004, PfCP2.9 generated a strong immune response with only mild side effects. In January 2008, Sinobiomed was awarded a 9 million RMB ($1.2 million) government grant for PfCP2.9 as part of China’s 863 Program that encourages technologically innovative products. More details...

Stock Symbol: (OTCBB: SOBM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here